Chiromics and Bristol-Myers Squibb Form Drug Discovery Strategic Alliance
PRINCETON, N.J. -- November 09, 2012
Chiromics LLC today announced a strategic research alliance with Bristol-Myers
Squibb Company (NYSE:BMY) which includes grants of non-exclusive license for
use of Chiromics’ chemical compound library, exclusive license to a
proprietary chemical compound collection, and a screening collaboration to
discover and optimize novel classes of small molecules against multiple
Chiromics’ compound collections are assembled using Chiromics’ core chemical
technology referred to as "cascade catalysis.” This technology was invented in
the MacMillan Laboratories at Princeton University. Cascade catalysis allows
for the creation of “accessible complexity,” a diverse collection of molecules
that is more complex than and differentiated from currently existing small
molecule collections, while retaining drug-like properties, the ability to
develop structure-activity relationships and ease of re-synthesis.
The synergistic combination of Chiromics’ chemical compound collection of
accessible complexity, and Chalis^TM, Chiromics’ exclusive hit recognition
algorithm for affinity selection, enables the identification of new lead
molecules that is complementary to conventional high throughput screening
Chiromics’ founder David MacMillan, Ph.D., James S. McDonnell Distinguished
University Professor of Chemistry and Chairman of the Chemistry Department at
Princeton University, stated, “We are delighted that Bristol-Myers Squibb has
chosen Chiromics as a drug discovery partner based on their proven commitment
to innovation and reputation as a strong collaborator with biotech companies.
This collaboration further authenticates that Chiromics’ chemical technology
and discovery platform is a unique gateway to a new set of small molecules for
About Chiromics LLC
Chiromics LLC is a drug discovery company that designs and synthesizes broadly
diverse chemical compound libraries, using a patented “cascade catalysis”
technology that produces drug-like molecules with a stereochemically defined
framework. The novel structures and accessible complexity of these compounds
expands the access to important disease targets and accelerates the
hit-to-lead time for identification of novel drugs.
Formed in 2009 and based in Princeton, N.J., Chiromics has established
collaborations with leading biotech and pharmaceutical companies for licensing
and screening of its libraries against a broad array of disease targets. For
more information, visit www.chiromics.com.
Colleen Plummer, 267-968-0827
Press spacebar to pause and continue. Press esc to stop.